Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Receives Final Approval from The USFDA for Lubiprostone Capsules, 8 mcg and 24 mcg
Details : Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. It is indicated for chronic idiopathic constipation and IBS with const...
Brand Name : Amitiza-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 24, 2023
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?